2026 Q1 -tulosraportti
11 päivää sitten
‧37 min
4,50 DKK/osake
Viimeisin osinko
6,37%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 15 | - | - | ||
| 58 | - | - | ||
| 214 | - | - | ||
| 496 | - | - | ||
| 20 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 5.3. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 21.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·26.5. · MuokattuScandinavian Tobacco Group – Updated price target after Q1 20 I have now reviewed Q1 2026 and updated my estimates a really bad Q4 2025. The financial report does not change the case – but it changes the pace. Q4 2025 was a clear low point. Q1 2026 shows stabilization – but not yet improvement. Part of the stabilization should however be seen in light of timing effects from Q4 2025, where ERP/SAP-related challenges affected invoicing and cash flow. Q1 therefore contains elements of normalization – not just real improvement. My updated levels: Fair Value (DCF): approx. 90–100 DKK Based on normalized free cash flow around 1.0 billion DKK, but with continued haircut for low ROIC and execution risk. Consensus price target: approx. 80–82 DKK The market prices stabilization – not turnaround. Base case: 82–85 DKK EPS ~10 and P/E 8–8.5x. Stabilization in 2026 without actual rerating – and with continued low multiple due to uncertainty about ROIC. Bull case: 95–100 DKK EPS 10.5–11 and P/E 9–10x. Improved cash flow, better margins and nascent market confidence. Bear case: 55–65 DKK EPS 8.5–9 and P/E 6.5–7x. Weak cash conversion, lack of improvement and continued low ROIC. Expected dividend 2026: 4.3–5.3 DKK Corresponding to approx. 6–7 % yield at current price. At a price around 70–75 DKK the stock trades: • Below fair value • Slightly below base case • But no longer extremely cheap - STG has gone from: Stable dividend stock → turnaround case. And that changes the rules of the game. Now it is not strategy that drives the case and it is not low P/E. The decisive factor for the investment case is not strategy – but execution. So management and the board must get to work - NOW Remember I am a happy amateur investor who has gotten too much time in my old age so take everything with a grain of salt.
·26.5.Well, I do think that you have done a serious piece of work here. Thanks for that.
·20.5. · MuokattuReasonable Q1 2026 report - especially considering that STG generally just has a tough time in every Q1. Better margins than expected, better performance in strategic areas, revenue largely within the expected median. Top-line level is in round figures on par with previously announced expectations, unfortunately. Cash flow approved. Tight cost control, which indicates that the actual financial figures are better than expected. But it must be expected that 2026 will be a weak dividend year. Looking forward to the presentation tomorrow. I'm super curious to hear if they mention anything about guidance 2030. My guess: It starts tomorrow at 6%-7% and lands at approx 4%.- ·16.5.The recent share price increase in both Philip Morris International (+10.9%) and British American Tobacco (+14.0%) is largely due to a significant easing of regulatory uncertainty in the USA. The FDA has signaled that they will not prioritize enforcement against nicotine products (pouches and vapes) that are already under an approval process, which has particularly raised expectations for products like ZYN, IQOS, Vuse, and Velo. At the same time, analyst upgrades and higher price targets have further strengthened investors' appetite. In contrast, STG faces a challenge not of regulation, but rather confidence in cash flow, capital allocation, and execution after a weak 2025. This underscores the difference in the case: where PMI and BAT are lifted by structural growth and regulatory clarity, STG is dependent on proving that the problems were temporary. I therefore hope that STG's management gains momentum on improvements in 2026 – because otherwise the stock risks being left behind with a falling share price level, while the rest of the sector moves on.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
11 päivää sitten
‧37 min
4,50 DKK/osake
Viimeisin osinko
6,37%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·26.5. · MuokattuScandinavian Tobacco Group – Updated price target after Q1 20 I have now reviewed Q1 2026 and updated my estimates a really bad Q4 2025. The financial report does not change the case – but it changes the pace. Q4 2025 was a clear low point. Q1 2026 shows stabilization – but not yet improvement. Part of the stabilization should however be seen in light of timing effects from Q4 2025, where ERP/SAP-related challenges affected invoicing and cash flow. Q1 therefore contains elements of normalization – not just real improvement. My updated levels: Fair Value (DCF): approx. 90–100 DKK Based on normalized free cash flow around 1.0 billion DKK, but with continued haircut for low ROIC and execution risk. Consensus price target: approx. 80–82 DKK The market prices stabilization – not turnaround. Base case: 82–85 DKK EPS ~10 and P/E 8–8.5x. Stabilization in 2026 without actual rerating – and with continued low multiple due to uncertainty about ROIC. Bull case: 95–100 DKK EPS 10.5–11 and P/E 9–10x. Improved cash flow, better margins and nascent market confidence. Bear case: 55–65 DKK EPS 8.5–9 and P/E 6.5–7x. Weak cash conversion, lack of improvement and continued low ROIC. Expected dividend 2026: 4.3–5.3 DKK Corresponding to approx. 6–7 % yield at current price. At a price around 70–75 DKK the stock trades: • Below fair value • Slightly below base case • But no longer extremely cheap - STG has gone from: Stable dividend stock → turnaround case. And that changes the rules of the game. Now it is not strategy that drives the case and it is not low P/E. The decisive factor for the investment case is not strategy – but execution. So management and the board must get to work - NOW Remember I am a happy amateur investor who has gotten too much time in my old age so take everything with a grain of salt.·26.5.Well, I do think that you have done a serious piece of work here. Thanks for that.
- ·20.5. · MuokattuReasonable Q1 2026 report - especially considering that STG generally just has a tough time in every Q1. Better margins than expected, better performance in strategic areas, revenue largely within the expected median. Top-line level is in round figures on par with previously announced expectations, unfortunately. Cash flow approved. Tight cost control, which indicates that the actual financial figures are better than expected. But it must be expected that 2026 will be a weak dividend year. Looking forward to the presentation tomorrow. I'm super curious to hear if they mention anything about guidance 2030. My guess: It starts tomorrow at 6%-7% and lands at approx 4%.
- ·16.5.The recent share price increase in both Philip Morris International (+10.9%) and British American Tobacco (+14.0%) is largely due to a significant easing of regulatory uncertainty in the USA. The FDA has signaled that they will not prioritize enforcement against nicotine products (pouches and vapes) that are already under an approval process, which has particularly raised expectations for products like ZYN, IQOS, Vuse, and Velo. At the same time, analyst upgrades and higher price targets have further strengthened investors' appetite. In contrast, STG faces a challenge not of regulation, but rather confidence in cash flow, capital allocation, and execution after a weak 2025. This underscores the difference in the case: where PMI and BAT are lifted by structural growth and regulatory clarity, STG is dependent on proving that the problems were temporary. I therefore hope that STG's management gains momentum on improvements in 2026 – because otherwise the stock risks being left behind with a falling share price level, while the rest of the sector moves on.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 15 | - | - | ||
| 58 | - | - | ||
| 214 | - | - | ||
| 496 | - | - | ||
| 20 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 5.3. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 21.5.2025 |
2026 Q1 -tulosraportti
11 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 26.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 5.3. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 21.5.2025 |
4,50 DKK/osake
Viimeisin osinko
6,37%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·26.5. · MuokattuScandinavian Tobacco Group – Updated price target after Q1 20 I have now reviewed Q1 2026 and updated my estimates a really bad Q4 2025. The financial report does not change the case – but it changes the pace. Q4 2025 was a clear low point. Q1 2026 shows stabilization – but not yet improvement. Part of the stabilization should however be seen in light of timing effects from Q4 2025, where ERP/SAP-related challenges affected invoicing and cash flow. Q1 therefore contains elements of normalization – not just real improvement. My updated levels: Fair Value (DCF): approx. 90–100 DKK Based on normalized free cash flow around 1.0 billion DKK, but with continued haircut for low ROIC and execution risk. Consensus price target: approx. 80–82 DKK The market prices stabilization – not turnaround. Base case: 82–85 DKK EPS ~10 and P/E 8–8.5x. Stabilization in 2026 without actual rerating – and with continued low multiple due to uncertainty about ROIC. Bull case: 95–100 DKK EPS 10.5–11 and P/E 9–10x. Improved cash flow, better margins and nascent market confidence. Bear case: 55–65 DKK EPS 8.5–9 and P/E 6.5–7x. Weak cash conversion, lack of improvement and continued low ROIC. Expected dividend 2026: 4.3–5.3 DKK Corresponding to approx. 6–7 % yield at current price. At a price around 70–75 DKK the stock trades: • Below fair value • Slightly below base case • But no longer extremely cheap - STG has gone from: Stable dividend stock → turnaround case. And that changes the rules of the game. Now it is not strategy that drives the case and it is not low P/E. The decisive factor for the investment case is not strategy – but execution. So management and the board must get to work - NOW Remember I am a happy amateur investor who has gotten too much time in my old age so take everything with a grain of salt.·26.5.Well, I do think that you have done a serious piece of work here. Thanks for that.
- ·20.5. · MuokattuReasonable Q1 2026 report - especially considering that STG generally just has a tough time in every Q1. Better margins than expected, better performance in strategic areas, revenue largely within the expected median. Top-line level is in round figures on par with previously announced expectations, unfortunately. Cash flow approved. Tight cost control, which indicates that the actual financial figures are better than expected. But it must be expected that 2026 will be a weak dividend year. Looking forward to the presentation tomorrow. I'm super curious to hear if they mention anything about guidance 2030. My guess: It starts tomorrow at 6%-7% and lands at approx 4%.
- ·16.5.The recent share price increase in both Philip Morris International (+10.9%) and British American Tobacco (+14.0%) is largely due to a significant easing of regulatory uncertainty in the USA. The FDA has signaled that they will not prioritize enforcement against nicotine products (pouches and vapes) that are already under an approval process, which has particularly raised expectations for products like ZYN, IQOS, Vuse, and Velo. At the same time, analyst upgrades and higher price targets have further strengthened investors' appetite. In contrast, STG faces a challenge not of regulation, but rather confidence in cash flow, capital allocation, and execution after a weak 2025. This underscores the difference in the case: where PMI and BAT are lifted by structural growth and regulatory clarity, STG is dependent on proving that the problems were temporary. I therefore hope that STG's management gains momentum on improvements in 2026 – because otherwise the stock risks being left behind with a falling share price level, while the rest of the sector moves on.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 15 | - | - | ||
| 58 | - | - | ||
| 214 | - | - | ||
| 496 | - | - | ||
| 20 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt